

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

**Date of Report: June 26, 2017  
Commission File Number: 001-36891**

**Collectis S.A.**

(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry  
75013 Paris, France  
+33 1 81 69 16 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

---

**EXHIBIT INDEX**

**Exhibit**      **Title**

99.1      Press release, dated **June 26, 2017**.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**CELLECTIS S.A.**  
(Registrant)

**June 26, 2017**

By: /s/ André Choulika  
André Choulika  
Chief Executive Officer

**Collectis S.A. Reports Results from Annual General Meeting Held on June 26, 2017**

NEW YORK--(BUSINESS WIRE)--June 26, 2017--Regulatory News:

Collectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) Shareholders' General Meeting (Alternext: ALCLS - Nasdaq: CLLS) was held on Monday, June 26, 2017 in Paris, at its head office.

At the meeting, during which more than 73% of voting rights were exercised, all the resolutions for which the management recommended a vote in favor, were adopted.

The resolutions adopted by Collectis' shareholders included:

- Appointment of two new directors to the board of directors, Mr Rainer Boehm and Mr Hervé Hoppenot;
- Renewal of the term of office of Director of Mr Laurent Arthaud, Mr Pierre Bastid and Mrs Annick Schwebig;
- Approval of the annual financial statements for the financial year ended December 31, 2016;
- Approval of the consolidated financial statements for the financial year ended December 31, 2016.

The full results of the vote can be examined on the company's website <https://www.collectis.com/en/investors/general-meetings/>.

**About Collectis**

Collectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 17 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Collectis uses the power of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering technologies, Collectis' goal is to create innovative products in multiple fields and with various target markets.

Collectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: [www.collectis.com](http://www.collectis.com).

Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Collectis Group.

---

**Disclaimer**

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Collectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

---

CONTACT:

**Collectis S.A.**

**Media:**

Jennifer Moore, 917-580-1088

VP of Communications

[media@collectis.com](mailto:media@collectis.com)

or

Caitlin Kasunich, 212-896-1241

KCSA Strategic Communications

[ckasunich@kcsa.com](mailto:ckasunich@kcsa.com)

or

**IR:**

Simon Harnest, 646-385-9008

VP of Corporate Strategy and Finance

[simon.harnest@collectis.com](mailto:simon.harnest@collectis.com)